Key result
LGE in dilated cardiomyopathy is linked to ~2.1-fold higher all-cause mortality.
Why the study?
Although the prognostic value of CMR-derived late gadolinium enhancement is well studied and new metrics have emerged, controversies remain regarding its role in precise risk stratification for dilated cardiomyopathy.
Does the presence, extent, location, and pattern of late gadolinium enhancement (LGE) on cardiovascular magnetic resonance predict adverse outcomes in patients with dilated cardiomyopathy?
Meta-Analysis (n=7,330)
Does the presence, extent, location, and pattern of late gadolinium enhancement (LGE) on cardiovascular magnetic resonance predict adverse outcomes in patients with dilated cardiomyopathy?
Hazard Ratio: 2.14 (95% CI 1.68–2.72)
Absolute Event Rate: 6.2% vs 3.2%
p-value: p=<0.001
Late gadolinium enhancement on cardiovascular magnetic resonance is a strong, independent predictor of arrhythmic events and mortality in patients with dilated cardiomyopathy, with predictive value varying by LGE extent, location, and pattern.
BACKGROUND The prognostic value of late gadolinium enhancement (LGE) derived from cardiovascular magnetic resonance (CMR) is well studied, and several new metrics of LGE have emerged. However, some controversies remain; therefore, further discussion is needed, and more precise risk stratification should be explored. AIM To investigate the associations between the positivity, extent, location, and pattern of LGE and multiple outcomes in dilated cardiomyopathy (DCM). METHODS PubMed, Ovid MEDLINE, and Cochrane Library were searched for studies that investigated the prognostic value of LGE in patients with DCM. Pooled hazard ratios (HRs) and 95% confidence intervals were calculated to assess the role of LGE in the risk stratification of DCM. RESULTS Nineteen studies involving 7330 patients with DCM were included in this meta-analysis and covered a wide spectrum of DCM, with a mean left ventricular ejection fraction between 21% and 50%. The meta-analysis revealed that the presence of LGE was associated with an increased risk of multiple adverse outcomes (all-cause mortality, HR: 2.14; arrhythmic events, HR: 5.12; and composite endpoints, HR: 2.38; all P < 0.001). Furthermore, every 1% increment in the extent of LGE was associated with an increased risk of all-cause mortality. Analysis of a subgroup revealed that the prognostic value varied based on different location and pattern of LGE. Additionally, we found that LGE was a stronger predictor of arrhythmic events in patients with greater left ventricular ejection fraction. CONCLUSION LGE by CMR in patients with DCM exhibited a substantial value in predicting adverse outcomes, and the extent, location, and pattern of LGE could provide additional information for risk stratification.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2023) conducted a meta-analysis in Dilated cardiomyopathy (DCM) (n=7,330). Late gadolinium enhancement (LGE) vs. Absence of late gadolinium enhancement (LGE) was evaluated on All-cause mortality (HR 2.14, 95% CI 1.68-2.72, p=<0.001). The presence of late gadolinium enhancement in patients with dilated cardiomyopathy was associated with a significantly increased risk of all-cause mortality (HR 2.14).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: